Genmab — December 2016
-
Aleau...Der er intet af der foregår nu som jeg ikke har set mange gange før i Genmab eller andre aktier.
-
-
AB er gået helt kold. ingen bevægelse i netto ???
-
tror den måske pludselig vender nordpå
-
Novod om Bluebird "We have previously (in our large case report on Genmab titled “Moving to the next frontier”) highlighted and discussed these issues and believe that the Genmab approach, with focus on bispecific antibodies (DuoBody) as an alternative to CAR-T, will be much more feasible, safety-wise and commercially. As a further read-across to Genmab, we see BCMA being a very interesting target in multiple myeloma and believe the data reported yesterday supports BCMA as a target.
-
Denne JNJ BCMA duobody, er den indlicenseret fra Genmab?
-
Det må være denne her https://ash.confex.com/ash/2016/webprogram/Paper91923.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind